Bicycle Therapeutics (BCYC) Competitors $8.15 -0.36 (-4.23%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. AMRX, OGN, MIRM, APLS, DNLI, VCEL, NAMS, AAPG, KYMR, and BHVNShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Amneal Pharmaceuticals Organon & Co. Mirum Pharmaceuticals Apellis Pharmaceuticals Denali Therapeutics Vericel NewAmsterdam Pharma Ascentage Pharma Group International Kymera Therapeutics Biohaven Amneal Pharmaceuticals (NASDAQ:AMRX) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk. Is AMRX or BCYC more profitable? Amneal Pharmaceuticals has a net margin of -6.88% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-6.88% -346.26% 4.85% Bicycle Therapeutics -450.64%-27.35%-20.81% Do analysts rate AMRX or BCYC? Amneal Pharmaceuticals currently has a consensus target price of $11.50, suggesting a potential upside of 54.99%. Bicycle Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 193.77%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has more risk and volatility, AMRX or BCYC? Amneal Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Does the media refer more to AMRX or BCYC? In the previous week, Amneal Pharmaceuticals had 6 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 5 mentions for Bicycle Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 0.97 beat Bicycle Therapeutics' score of 0.46 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in AMRX or BCYC? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in AMRX or BCYC? Bicycle Therapeutics received 126 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.24% of users gave Amneal Pharmaceuticals an outperform vote while only 70.53% of users gave Bicycle Therapeutics an outperform vote. CompanyUnderperformOutperformAmneal PharmaceuticalsOutperform Votes2095.24% Underperform Votes14.76%Bicycle TherapeuticsOutperform Votes14670.53% Underperform Votes6129.47% Which has better earnings and valuation, AMRX or BCYC? Amneal Pharmaceuticals has higher revenue and earnings than Bicycle Therapeutics. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.83B0.82-$83.99M-$0.04-185.50Bicycle Therapeutics$25.72M22.91-$180.66M-$3.14-2.71 SummaryAmneal Pharmaceuticals beats Bicycle Therapeutics on 10 of the 18 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$589.35M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-2.599.1426.7920.05Price / Sales22.91255.59394.72116.44Price / CashN/A65.8538.2534.62Price / Book0.696.546.864.61Net Income-$180.66M$143.51M$3.22B$248.19M7 Day Performance6.24%5.60%6.83%2.97%1 Month Performance13.32%10.06%13.73%16.58%1 Year Performance-60.60%-0.86%18.22%8.16% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.6819 of 5 stars$8.15-4.2%$25.00+206.7%-60.8%$564.42M$25.72M-2.48240Gap UpAMRXAmneal Pharmaceuticals3.3094 of 5 stars$7.60+2.6%$11.50+51.3%+10.3%$2.36B$2.83B-11.187,600Gap UpOGNOrganon & Co.4.7775 of 5 stars$8.69-0.2%$18.00+107.1%-59.8%$2.26B$6.29B2.6110,000High Trading VolumeMIRMMirum Pharmaceuticals4.1281 of 5 stars$45.57+2.9%$59.00+29.5%+79.2%$2.25B$379.25M-22.56140News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.0974 of 5 stars$17.52+1.3%$41.37+136.1%-57.2%$2.20B$781.37M-8.63770Gap UpDNLIDenali Therapeutics4.4646 of 5 stars$14.80+3.0%$33.79+128.3%-29.0%$2.15B$330.53M-5.36430Analyst ForecastVCELVericel2.5802 of 5 stars$42.65+2.2%$60.86+42.7%-14.9%$2.14B$238.54M710.95300Positive NewsNAMSNewAmsterdam Pharma2.7057 of 5 stars$19.22+4.6%$43.00+123.7%-2.5%$2.11B$45.56M-10.224AAPGAscentage Pharma Group InternationalN/A$24.20-0.5%N/AN/A$2.11B$980.65M0.00600Gap UpKYMRKymera Therapeutics2.5499 of 5 stars$32.17+7.0%$55.53+72.6%-12.7%$2.09B$47.07M-13.75170Analyst ForecastGap DownBHVNBiohaven3.5164 of 5 stars$20.47+1.1%$62.54+205.5%-58.7%$2.09BN/A-2.19239Analyst DowngradeGap Down Related Companies and Tools Related Companies Amneal Pharmaceuticals Competitors Organon & Co. Competitors Mirum Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Denali Therapeutics Competitors Vericel Competitors NewAmsterdam Pharma Competitors Ascentage Pharma Group International Competitors Kymera Therapeutics Competitors Biohaven Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCYC Stock Free BCYC Stock Alerts